Trichy Daily

Small Lymphocytic Lymphoma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Small Lymphocytic Lymphoma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
19:24 2023
Small Lymphocytic Lymphoma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including Small Lymphocytic Lymphoma clinical trials and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Small Lymphocytic Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Small Lymphocytic Lymphoma clinical trials studies, Small Lymphocytic Lymphoma NDA approvals (if any), and product development activities comprising the technology, Small Lymphocytic Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Small Lymphocytic Lymphoma Pipeline Report

 

  • DelveInsight’s Small Lymphocytic Lymphoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small Lymphocytic Lymphoma.

 

  • The leading Small Lymphocytic Lymphoma Companies includes Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others.

 

  • Promising Small Lymphocytic Lymphoma Pipeline Therapies includes ABT-199, Rituximab, Ibrutinib, Bendamustine hydrochloride, Post-Chlorambucil Therapy Follow-up, ofatumumab, venetoclax, TG02 citrate, Acalabrutinib, Chlorambucil, and others.

 

  • The Small Lymphocytic Lymphoma companies and academics are working to assess challenges and seek opportunities that could influence Small Lymphocytic Lymphoma R&D. The Small Lymphocytic Lymphoma pipeline therapies under development are focused on novel approaches to treat/improve Small Lymphocytic Lymphoma.

 

 

To explore more information on the latest breakthroughs in the Small Lymphocytic Lymphoma Pipeline treatment landscape of the report, click here @ Small Lymphocytic Lymphoma Pipeline Outlook

 

Small Lymphocytic Lymphoma Overview

Small Lymphocytic Lymphoma is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease.  Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood. SLL that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body).

 

Small Lymphocytic Lymphoma Emerging Drugs Profile

 

TQ-B3525: Chia Tai Tianqing Pharmaceutical Group

TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

 

LOXO-305: Loxo Oncology

Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma. Currently available BTK inhibitors irreversibly inhibit BTK and the long-term efficacy of these therapies can be limited by acquired resistance. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. Pirtobrutinib is currently being studied in multiple clinical trials. Safety and efficacy have not been established for the uses being studied.

 

IOV 2001: Iovance Biotherapeutics

IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

 

 

Request a sample and discover the recent advances in Small Lymphocytic Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Small Lymphocytic Lymphoma Treatment Landscape

 

Small Lymphocytic Lymphoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.

 

DelveInsight’s Small Lymphocytic Lymphoma Pipeline Report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

For further information, refer to the detailed Small Lymphocytic Lymphoma Unmet Needs, Small Lymphocytic Lymphoma Market Drivers, and Market Barriers, click here for Small Lymphocytic Lymphoma Ongoing Clinical Trial Analysis

 

Scope of the Small Lymphocytic Lymphoma Pipeline Report

 

  • Coverage- Global

 

  • Small Lymphocytic Lymphoma Companies- Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others.
  • Small Lymphocytic Lymphoma Pipeline Therapies- ABT-199, Rituximab, Ibrutinib, Bendamustine hydrochloride, Post-Chlorambucil Therapy Follow-up, ofatumumab, venetoclax, TG02 citrate, Acalabrutinib, Chlorambucil, and others.

 

  • Small Lymphocytic Lymphoma Pipeline Segmentation: Phases, Product Type, Molecule Type, Mechanism of action, Route of Administration 

 

Dive deep into rich insights for drugs for Small Lymphocytic Lymphoma Market Drivers and Small Lymphocytic Lymphoma Market Barriers, click here @ Small Lymphocytic Lymphoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Small Lymphocytic Lymphoma Executive Summary
  3. Small Lymphocytic Lymphoma: Overview
  4. Small Lymphocytic Lymphoma Pipeline Therapeutics
  5. Small Lymphocytic Lymphoma Therapeutic Assessment
  6. Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name: Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. LOXO-305: Loxo Oncology
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase I/II)
  14. TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Small Lymphocytic Lymphoma Key Companies
  21. Small Lymphocytic Lymphoma Key Products
  22. Small Lymphocytic Lymphoma – Unmet Needs
  23. Small Lymphocytic Lymphoma – Market Drivers and Barriers
  24. Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
  25. Small Lymphocytic Lymphoma Analyst Views
  26. Small Lymphocytic Lymphoma Key Companies
  27. Appendix

Got Queries? Find out the related information on Small Lymphocytic Lymphoma Mergers and acquisitions, Small Lymphocytic Lymphoma licensing activities @ Small Lymphocytic Lymphoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Related Articles